Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19.
|
| Abstract |
Type-I interferons (IFNs) mediate antiviral activity and have emerged as important immune mediators during coronavirus disease 19 (COVID-19). Several lines of evidence suggest that impaired type-I IFN signaling may predispose to severe COVID-19. However, the pathophysiologic mechanisms that contribute to illness severity remain unclear. In this study, our goal was to gain insight into how type-I IFNs influence outcomes in patients with COVID-19. To achieve this goal, we compared clinical outcomes between 26 patients with neutralizing type-I IFN autoantibodies (AAbs) and 192 patients without AAbs who were hospitalized for COVID-19 at three Italian hospitals. The presence of circulating AAbs to type-I IFNs was associated with an increased risk of admission to the intensive care unit and a delayed time to viral clearance. However, survival was not adversely affected by the presence of type-I IFN AAbs. Our findings provide further support for the role of type-I IFN AAbs in impairing host antiviral defense and promoting the development of critical COVID-19 pneumonia in severe acute respiratory syndrome coronavirus 2-infected individuals.
|
|---|---|
| Authors | Michael S Abers, Lindsey B Rosen, Ottavia M Delmonte, Elana Shaw, Paul Bastard, Luisa Imberti, Virginia Quaresima, Andrea Biondi, Paolo Bonfanti, Riccardo Castagnoli, Jean-Laurent Casanova, Helen C Su, Luigi D Notarangelo, Steven M Holland, Michail S Lionakis |
| Journal | Immunology and cell biology (Immunol Cell Biol) Vol. 99 Issue 9 Pg. 917-921 (10 2021) ISSN: 1440-1711 [Electronic] United States |
| PMID | 34309902 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't) |
| Copyright | © 2021 Australian and New Zealand Society for Immunology, Inc. This article has been contributed to by US Government employees and their work is in the public domain in the USA. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!